Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 76544

Title: Profiling of gene fusion involving targetable genes in Chinese gastric cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06048170
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Associate Professor
Reviewer's Country/Territory: South Korea
Author's Country/Territory: China

Manuscript submission date: 2022-03-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-01 08:56

Reviewer performed review: 2022-04-01 09:00

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This is an article to address Profiling of gene fusion involving targetable genes in Chinese gastric cancer. The authors concluded the landscape of fusions involving targetable genes in a Chinese GC cohort and found that 1.68% of patients with GC harbor potential targetable gene fusions, which were enriched slightly in patients with ERBB2 amplification. Gene fusion detection may provide a potential treatment strategy for patients with GC with disease progression following standard therapy. That is interesting and helpful. This study contributes to a potential treatment strategy for patients with GC with disease progression following standard therapy.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 76544

Title: Profiling of gene fusion involving targetable genes in Chinese gastric cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05196024
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Associate Professor
Reviewer's Country/Territory: United States
Author's Country/Territory: China

Manuscript submission date: 2022-03-30

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-05-13 18:36

Reviewer performed review: 2022-05-19 18:29

Review time: 5 Days and 23 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer	Peer-Review: [Y] Anonymous [ ] Onymous

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This manuscript is scientifically well done and overall well written. In some ways it is a shame that the authors did not find more targetable mutations which could be of benefit to this population of patients. I have a few minor comments to make the manuscript easier for readers who are not as familiar with gene sequencing and profiling to understand. Abstract, Methods line 3: Please define SNVs at first use Abstract , Conclusions, line 3: I recommend deleting the word "slightly" since in other places, such as the Core Tip, the authors simply say "enriched" Introduction, second paragraph, line 7: TCGA is The Cancer Genome Atlas; line 12, please define dMMR at first use Introduction, third paragraph, line 2: laRotrectinib is misspelled M&M, Mutational Profiling, first paragraph, second to last line: Please add "more THAN 25% OF regions" M&M, Mutational Profiling, second paragraph, line 5: Please define MSS as first use Results, Novel Fusions, line 7: Please define IGV at first use Discussion, second paragraph, line 5: Please delete the word "Although"